Pure Global
NCT03878420

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)

A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE II)
LumiThera, Inc.·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
Valeda PBM treatment
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
LumiThera, Inc.
Location
Nantes,Freiburg,Kiel,Mainz,Milano,Barcelona,Great Yarmouth,Peterborough, France,Germany,Italy,Spain,United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Feb 14, 2019
End date
Jan 22, 2021
Enrollment
44 participants
Primary outcome

Best Corrected Visual Acuity

Summary

This LIGHTSITE II study is a double-masked, sham-controlled, parallel design, prospective
 multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry
 AMD.

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03878420
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT03878420 through Pure Global AI's free database. This phase not specified trial is sponsored by LumiThera, Inc. and is currently Completed. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.